Straumann Holding AG (OTCMKTS:SAUHY – Get Free Report) was the recipient of a large decrease in short interest in August. As of August 14th, there was short interest totaling 1,001 shares, a decrease of 80.6% from the July 30th total of 5,152 shares. Based on an average trading volume of 47,320 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the company’s stock are short sold.
Straumann Price Performance
SAUHY traded down $0.13 during trading on Thursday, hitting $11.39. 6,279 shares of the company traded hands, compared to its average volume of 131,291. Straumann has a one year low of $9.44 and a one year high of $13.61. The stock’s fifty day moving average is $12.55 and its 200 day moving average is $11.69.
Analysts Set New Price Targets
A number of research analysts recently weighed in on SAUHY shares. Barclays reissued an “overweight” rating on shares of Straumann in a research report on Thursday, June 18th. Citigroup reaffirmed a “sell” rating on shares of Straumann in a research report on Thursday, July 9th. Deutsche Bank Aktiengesellschaft cut shares of Straumann from a “buy” rating to a “hold” rating in a research report on Friday, August 21st. BMO Capital Markets assumed coverage on Straumann in a research note on Wednesday, July 8th. They issued an “outperform” rating on the stock. Finally, Morgan Stanley reaffirmed an “underweight” rating on shares of Straumann in a report on Tuesday, June 30th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold”.
Straumann Company Profile
Straumann (OTCMKTS:SAUHY) is a Swiss-based dental technology company that develops, manufactures and markets restorative, regenerative and digital solutions for dental professionals. The company’s core offerings center on implant-supported restorations and components, biomaterials used for bone and soft-tissue regeneration, and a range of prosthetic products used by dentists and dental laboratories to restore oral function and aesthetics.
In addition to implant and biomaterial product lines, Straumann provides digital dentistry solutions that support treatment planning and workflows.
Further Reading
- Five stocks we like better than Straumann
- Semtech Stock Rallies on Strong Q2 Results and Raised Guidance
- Marvell’s Big AI Test Comes One Day After NVIDIA’s Blowout Quarter
- NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
- Alphabet Is Building a Base—Could a Breakout Be Next?
Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.
